CA Patent

CA3217521A1 — Methods of treating depression and anxiety

Assigned to Woolsey Pharmaceuticals Inc · Expires 2022-11-24 · 3y expired

What this patent protects

The invention relates to the treatment of patients with depression and or anxiety with low doses of rho kinase inhibitors. The maximum dose of a rho kinase inhibitor, based on fasudil hydrochloride as an exemplary agent, is less than 60 mg per day based on an immediate release fo…

USPTO Abstract

The invention relates to the treatment of patients with depression and or anxiety with low doses of rho kinase inhibitors. The maximum dose of a rho kinase inhibitor, based on fasudil hydrochloride as an exemplary agent, is less than 60 mg per day based on an immediate release formulation. Comparable dosing with other inhibitors is selected based on molar equivalents and/or rho kinase binding affinities. Treatable patients have one or more depressive disorders and/or one or more anxiety disorders

Drugs covered by this patent

Patent Metadata

Patent number
CA3217521A1
Jurisdiction
CA
Classification
—
Expires
2022-11-24
Drug substance claim
No
Drug product claim
No
Assignee
Woolsey Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.